Cystic liver disease program(Restari)

N/A

Report date: 2026/02/26 17:51:43
NME

Base Information

Drug NameCystic liver disease program(Restari)
Drug Alias NameSmall molecule for cystic liver disease(Restari)
ClassificationSmall molecules
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPolycystic Liver Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRestari
China Registration ClassN/A

Develop Information

Active CompaniesRestariAribio Co Ltd
Inactive CompaniesN/A
Active IndicationsPolycystic Liver Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A